ASLAN Cuts Costs, Jobs And Refocuses After Varlitinib Setback
Executive Summary
Singapore-based company prioritizes resources and cuts jobs following the recent Phase II failure of its lead pipeline asset in first-line gastric cancer.
You may also be interested in...
Asia Deal Watch: Everest Licenses Asia Rights To Calliditas’ IgA Nephropathy Candidate
While an orphan indication in the US and EU, IgAN accounts for 40% of glomerular disease in China; deal also confers rights in Hong Kong, Macau, Taiwan, Singapore. Also, Y-Biologics teams with Dualogics on bispecific antibodies for cancer.
ASLAN, Sosei Pipeline Assets Hit By Development Delays
Two Asia-based companies disclose delays to important clinical pipeline assets, one in oncology driven by apparent ethnic differences in response to prior therapy and the other a CNS molecule hit by an unexpected toxicity finding in an animal study.
ASLAN's Downsized US IPO Off To A Slump Start
Singapore venture ASLAN's US IPO has got off to a disappointing start, with the shares in what was already a downsized offering falling sharply in early trading.